{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:37:49Z","timestamp":1787769469406,"version":"build-2784847793"},"reference-count":50,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"An Nan Hospital, China Medical University","award":["ANHRF115-07"],"award-info":[{"award-number":["ANHRF115-07"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Objective: Radiotherapy remodels the tumor microenvironment (TME) and may enhance the efficacy of immunotherapy in cancer treatment, particularly in patients with large, unresectable hepatocellular carcinoma (HCC) complicated by portal vein tumor thrombus (PVTT). Because of these unique effects, a growing body of research has found that stereotactic body radiation therapy (SBRT) combined with transcatheter arterial chemoembolization (TACE) or programmed death protein 1 (PD-1) inhibitors has a synergistic impact on unresectable advanced hepatocellular carcinomas (HCCs) larger than 5 cm in diameter. We aim to explore the efficacy of these treatment modalities through a network meta-analysis (NMA). Methods and Analysis: We evaluated the efficacy and safety of different SBRT-based treatment modalities for large advanced HCCs with PVTT (tumor diameter \u2265 5 cm), with primary endpoints including overall survival (OS), progression-free survival (PFS), and grade 3\u20134 severe adverse events (SAEs). Results: Eighteen studies comprising 2303 patients were included. SBRT combined with transcatheter arterial chemoembolization (SBRT + TACE) demonstrated significantly superior overall survival compared with other monotherapy or combination strategies. Most other treatment regimens showed comparable PFS outcomes. Notably, SBRT alone and SBRT combined with PD 1 inhibitors (SBRT + PD 1) were associated with significantly lower incidences of severe adverse events compared with other treatment modalities; all of these reported SAEs were manageable with appropriate clinical intervention. Conclusions: For patients with large (\u22655 cm) advanced HCC with PVTT, SBRT combined with TACE was associated with superior OS and PFS compared with other treatment strategies. These findings suggest potential synergistic interactions between SBRT and TACE or immunotherapy. Further high-quality prospective trials are warranted to validate these observations and clarify the underlying molecular mechanisms. Our results provide evidence to inform therapeutic decision-making in advanced HCC.<\/jats:p>","DOI":"10.3390\/cancers18060988","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T17:12:26Z","timestamp":1773853946000},"page":"988","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Stereotactic Body Radiation Therapy Modalities for &gt;5 cm Advanced Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis"],"prefix":"10.3390","volume":"18","author":[{"given":"Henry W. C.","family":"Leung","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, An-Nan Hospital, China Medical University, Tainan 709, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyh-Yau","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiology, An-Nan Hospital, China Medical University, Tainan 709, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Hang","family":"Leung","sequence":"additional","affiliation":[{"name":"To Be Better One Aesthetic Clinic, Taipei City 100, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Sheng","family":"Tai","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, An-Nan Hospital, China Medical University, Tainan 709, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4071-8132","authenticated-orcid":false,"given":"Agnes L. F.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Research, An-Nan Hospital, China Medical University, Tainan 709, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"ref_1","first-page":"1","article-title":"Time to Debunk an Urban Myth? The \u201cAbscopal effect\u201d with Radiation and Anti-PD-1","volume":"39","author":"Tanguy","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41419-023-06211-2","article-title":"Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Navarro-Mart\u00edn, A., Galiana, I.L., Berenguer Frances, M.A., Cacicedo, J., Ca\u00f1as Cort\u00e9s, R., Comas Anton, S., Padrones S\u00e1nchez, S., Bol\u00edvar Cuevas, S., Parry, R., and Guedea Edo, F. (2018). Preliminary Study of the Effect of Stereotactic Body Radiotherapy (SBRT) on the Immune System in Lung Cancer Patients Unfit for Surgery: Immunophenotyping Analysis. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19123963"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/15384047.2016.1264543","article-title":"Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone","volume":"18","author":"Koller","year":"2017","journal-title":"Cancer Biol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs. Pembrolizumab Alone on Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jamaoncol.2023.2132","article-title":"Checkpoint Inhibitors in Combination with Stereotactic Body Radiotherapy in Patients with Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial","volume":"9","author":"Spaas","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Yu, J., Li, M., Ren, B., Cheng, L., Wang, X., Ma, Z., Yong, W.P., Chen, X., Wang, L., and Goh, B.C. (2023). Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: Factors, strategies, and ongoing trials. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1261575"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"104070","DOI":"10.1016\/j.critrevonc.2023.104070","article-title":"Combined immunotherapy for hepatocellular carcinoma: How to maximize immune checkpoint blockade synergic anti-tumor effect","volume":"189","author":"Huang","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s12072-022-10396-7","article-title":"Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: A single-arm trial","volume":"16","author":"Li","year":"2022","journal-title":"Hepatol. Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.3748\/wjg.v29.i24.3871","article-title":"Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial","volume":"29","author":"Chen","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Chen, Y., Hong, H., Fang, W., Zhang, X., Luo, H., Chen, Z., Yu, J., Fan, W., Chi, X., and Peng, Y. (2023). Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1113389"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijrobp.2022.09.052","article-title":"Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced\/Unresectable Hepatocellular Carcinoma","volume":"115","author":"Juloori","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_14","unstructured":"NCCN (2025). Clinical Practice Guidelines in Oncology, Hepatocellular Carcinoma, NCCN. [2nd ed.]."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment 428 comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Statist Med."},{"key":"ref_18","unstructured":"Cochrane Collaboration (2025, August 25). Review Manager (RevMan) Computer Program, Available online: https:\/\/training.cochrane.org\/system\/files\/uploads\/protected_file\/RevMan5.4_user_guide.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/2046-4053-3-110","article-title":"Microsoft-Excel-based tool for running and critically appraising network meta-analyses--an overview and application of NetMetaXL","volume":"3","author":"Brown","year":"2014","journal-title":"Syst. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/jrsm.1373","article-title":"MetaInsight: An interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta","volume":"10","author":"Owen","year":"2019","journal-title":"Res. Synth. Methods"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Dias, S., Ades, A.E., Welton, N.J., Jansen, J.P., and Sutton, A.J. (2018). Chapter 3 MODEL Fit, Model Comparison and Outlier Detection. Network Meta-Anlaysis for Decision-Making, John Wiley & Sons Ltd.","DOI":"10.1002\/9781118951651"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Su, T.S., Lu, H.Z., Cheng, T., Zhou, Y., Huang, Y., Gao, Y.C., Tang, M.Y., Jiang, H.Y., Lian, Z.P., and Hou, E.C. (2016). Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2894-9"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.suronc.2019.01.006","article-title":"Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis","volume":"28","author":"Wong","year":"2019","journal-title":"Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijrobp.2019.05.066","article-title":"Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma","volume":"105","author":"Shen","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Su, T.S., Liang, P., Zhou, Y., Huang, Y., Cheng, T., Qu, S., Chen, L., Xiang, B.D., Zhao, C., and Huang, D.J. (2020). Stereotactic Body Radiation Therapy vs. Transarterial Chemoembolization in Inoperable Barcelona Clinic Liver Cancer Stage a Hepatocellular Carcinoma: A Retrospective, Propensity-Matched Analysis. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00347"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s12072-021-10173-y","article-title":"Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis","volume":"15","author":"Li","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Chiang, C.L., Chiu, K.W., Lee, F.A., Kong, F.S., and Chan, A.C. (2021). Combined Stereotactic Body Radiotherapy and Immunotherapy Versus Transarterial Chemoembolization in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.798832"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Li, C., Liao, W., Huang, Y., and Wang, Z. (2022). A Combination of Sorafenib, an Immune Checkpoint Inhibitor, TACE and Stereotactic Body Radiation Therapy versus Sorafenib and TACE in Advanced Hepatocellular Carcinoma Accompanied by Portal Vein Tumor Thrombus. Cancers, 14.","DOI":"10.3390\/cancers14153619"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Xiang, Y.J., Wang, K., Zheng, Y.T., Feng, S., Yu, H.M., Li, X.W., Cheng, X., Cheng, Y.Q., Feng, J.K., and Zhou, L.P. (2022). Effects of Stereotactic Body Radiation Therapy Plus PD-1 Inhibitors for Patients with Transarterial Chemoembolization Refractory. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.839605"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000533425","article-title":"Survival Outcome Analysis of Stereotactic Body Radiotherapy and Immunotherapy (SBRT-IO) versus SBRT-Alone in Unresectable Hepatocellular Carcinoma","volume":"13","author":"Chiang","year":"2024","journal-title":"Liver Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13014-023-02270-z","article-title":"Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: A retrospective study","volume":"18","author":"Ji","year":"2023","journal-title":"Radiat. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1007\/s00432-023-04652-y","article-title":"Comparison of stereotactic body radiotherapy with and without lenvatinib for advanced hepatocellular carcinoma: A propensity score analysis","volume":"149","author":"Wang","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.ijrobp.2024.03.035","article-title":"Stereotactic Body Radiotherapy Combined with Lenvatinib with or Without PD-1 Inhibitors as Initial Treatment for Unresectable Hepatocellular Carcinoma","volume":"120","author":"Wang","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13014-024-02527-1","article-title":"Stereotactic body radiotherapy versus lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis: A propensity matching score analysis","volume":"19","author":"Ji","year":"2024","journal-title":"Radiat. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Zhang, M., Zheng, Z., Ding, Q., Su, J., Xin, Y., and Jiang, X. (2024). Radiotherapy plus lenvatinib versus radiotherapy plus sorafenib for hepatocellular carcinoma with portal vein tumor thrombus: A retrospective study. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1458819"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s12072-025-10794-7","article-title":"Efficacy and safety of radiotherapy versus transarterial chemoembolization in combination with lenvatinib and camrelizumab for hepatocellular carcinoma with inferior vena cava\/right atrium tumor thrombus: A multicenter study","volume":"19","author":"Huang","year":"2025","journal-title":"Hepatol. Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1245\/s10434-024-16456-6","article-title":"Outcomes of Stereotactic Body Radiotherapy Compared with Surgical Resection in Patients with Hepatocellular Carcinoma and Macrovascular Invasion: A Propensity Score-Matched Analysis","volume":"32","author":"Yan","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","article-title":"Stereotactic Body Radiotherapy vs. Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology\/RTOG 1112 Phase 3 Randomized Clinical Trial","volume":"11","author":"Dawson","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jhep.2018.02.008","article-title":"Hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin vs. sorafenib for advanced hepatocellular carcinoma","volume":"69","author":"Lyu","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.21037\/atm-20-4164","article-title":"Combined locoregional and systemic therapy for advanced hepatocellular carcinoma: Finally, the future is obscure","volume":"8","author":"Farsad","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Miksad, R.A., Ogasawara, S., Xia, F., Fellous, M., and Piscaglia, F. (2019). Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: The LiverT study. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5989-2"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Piening, A., Swaminath, A., Dombrowski, J., Teague, R.M., Al-Hammadi, N., and Shahi, J. (2023). Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic body radiation therapy or systemic therapy alone. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1290691"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Jiang, C., Jing, S., Zhou, H., Li, A., Qiu, X., Zhu, X., and Shen, Z. (2021). Efficacy and Prognostic Factors of Trans-Arterial Chemoembolization Combined with Stereotactic Body Radiation Therapy for BCLC Stage B Hepatocellular Carcinoma. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.640461"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy Combined with Immunotherapy: The Dawn of Cancer Treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e70005.44","DOI":"10.1002\/lci2.70005","article-title":"Stereotactic Body Radiation Therapy Combined with Immunotherapy for Patients with Hepatocellular Carcinoma-A Review","volume":"5","author":"Patel","year":"2024","journal-title":"Liver Int. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/hep.30666","article-title":"Sorafenib induces pyroptosis in macrophages and triggers natural killer cell\u2013mediated cytotoxicity against hepatocellular carcinoma","volume":"70","author":"Hage","year":"2019","journal-title":"Hepatology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cpt.2025.04.004","article-title":"Advances in transarterial chemoembolization for hepatocellular carcinoma: Integration with systemic therapies and emerging treatment strategies","volume":"4","author":"Sutanto","year":"2025","journal-title":"Cancer Pathog. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Li, Q., Han, J., Yang, Y., and Chen, Y. (2022). PD-1\/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1070961"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Miljanic, M., Montalvo, S., Aliru, M., Song, T., Leon-Camarena, M., Innella, K., Vujovic, D., Komaki, R., and Iyengar, P. (2022). The Evolving Interplay of SBRT and the Immune System, Along with Future Directions in the Field. Cancers, 14.","DOI":"10.3390\/cancers14184530"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1007\/s00270-024-03813-x","article-title":"Transarterial Embolization Enhances Programmed Cell Death Ligand 1 Expression and Influences CD8+T Lymphocytes Cytotoxicity in an Orthotopic Hepatocellular Carcinoma Rat Model","volume":"47","author":"Zhang","year":"2024","journal-title":"Cardiovasc. Interv. Radiol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/6\/988\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T17:17:43Z","timestamp":1773854263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/6\/988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["cancers18060988"],"URL":"https:\/\/doi.org\/10.3390\/cancers18060988","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]}}}